PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses

Medications leveraging the leptin, PCSK9, ANGPTL3 and FABP4 pathways are being developed for the treatment of insulin resistance and/or lipid disorders. To evaluate whether these pathways are independent from each other, we assessed the levels of PCSK9, ANGPTL3 and FABP4, in normal subjects and subjects exhibiting HIV and highly active antiretroviral therapy (HAART) induced metabolic syndrome with lipoatrophy and hypoleptinemia. Studies were performed at baseline and during food deprivation for three days with either a placebo or leptin administration at physiological replacement doses to correct fasting induced acute hypoleptinemia and in pharmacological doses.

Source: Metabolism - Clinical and Experimental - July 9, 2022 Category: Biomedical Science Authors: Eirini Bouzoni, Nikolaos Perakakis, Margery A. Connelly, Angeliki M. Angelidi, Eleni Pilitsi, Olivia Farr, Konstantinos Stefanakis, Christos S. Mantzoros Source Type: research